Table 1.

Characteristics of the main randomized controlled trials.

Clinical Trial	Number	Gender	Age	Intervention	Treatment Duration	Primary Outcomes	Adverse Events
Revicki et al. [1]	A: 208	A: M 157; F 51	A: 41.7	Adalimumab40 mgs.c. eow	24	ASAS20, ASAS40, BASDAI, SF-36	NA
	P: 107	P: M 79; F 28	P: 43.4
Huang et al. [55]	A: 229	A: M 185; F 44	A: 30.1	As above	12	ASAS20, ASAS40, BASDAI50, CRP, HAQ-S, SF-36	AE, serious AE, drug discontinuation, infection, serious infections
	P: 115	P: M 95; F 20	P: 29.6
Sieper et al. [60]	A: 91	A: M 44; F 47	A: 37	As above	12	ASAS20, ASDAS,BASDAI, BASDAI50,SF-36, HAQ-S	AE, serious AE, drug discontinuation, infection, serious infections
	P: 94	P: M 40; F 54	P: 38.4
Davis et al. [91]	A: 208	A: M 157; F 51	A: 41.7	As above	24	ASAS20, ASAS40, BASDAI, ASQoL, SF-36	NA
	P: 107	P: M 79; F 28	P: 43.4
Hu et al. [91]	A: 26	A: M 24; F 2	A: 28.2	As above	24	BASDAI, BASFI, CRP, ASDAS	NA
	P: 20	P: M 20; F 0	P: 27.4
van der Heijde et al. [91]	A: 208	A: M 236; F 79	A: 42.2	As above	12/24 rescue	BASFI, BASDAI, SF-36, ASQoL	AE, serious AE, drug discontinuation, infection, serious infections
	P: 107	P: M 219; F 69	P: 42.4

Abbreviations: A, adalimumab group; P, placebo group; M, male; F, female; s.c., subcutaneously; eow, every other week; ASAS, Assessment in AS International Working Group; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; SF-36, Short Form 36; BASFI, Bath Ankylosing Spondylitis Functional Index; HAQ-S, Health Assessment Questionnaire modified for Spondyloarthropathies; ASDAS, Ankylosing Spondylitis Disease Activity Score; ASQoL, Ankylosing Spondylitis Quality of Life questionnaire; AE, adverse events; NA, not applicable.